Loading...
The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 10(6)) into immune competent syngeneic hosts, but not immune deficient mice. A...
Na minha lista:
| Udgivet i: | Molecules |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6600265/ https://ncbi.nlm.nih.gov/pubmed/31212694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules24112192 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|